The newest perspectives on the treatment of glioblastoma multiforme;Najnowsze perspektywy w leczeniu glejaka wielopostaciowego

Polski Merkuriusz Lekarski

Volumn 37, Issue 218, 2014, Pages 119-123

  Cholewa, Hanna ^a   Duda, Katarzyna ^a   Łabuzek, Krzysztof ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bevacizumab; Glioblastoma multiforme; MicroRNA; Stereotactic radiosurgery

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY;

BRAIN TUMOR; GLIOBLASTOMA; HUMAN; RADIOSURGERY; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; RADIOSURGERY;

EID: 84908048889     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Bader AG: miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet, 2012;3(120).
2. Bader AG, Brown D, Stoudemire J, et al.: Developing therapeutic microRNAs for cancer. Gene Ther, 2011;18(12):1121-6.
3. Bao S, Wu Q, McLendon RE, et al.: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006;444(7120):756-60.
4. Beilo L, Giussani C, Carrabba G, et al.: Angiogenesis and invasion in gliomas. Cancer Treat Res, 2004;117:263-84.
5. Binello E, Germano IM: Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci, 2011;102(11):1958-66.
6. Bregy A, Wong TM, Shah AH, et al.: Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev, 2013;39(8):891-907.
7. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer, 2006;6(11):857-66.
8. Chamberlain MC: Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol, 2011;5:117-29.
9. Chowdhary S, Chamberlain M: Bevacizumab for the treatment of glioblastoma. Expert Rev Neurother, 2013;13(8):937-49.
10. Cuneo KC, Vredenburgh JJ, Sampson JH, et al.: Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys, 2012;82(5):2018-24.
11. Deng S, Calin GA, Croce CM, et al.: Mechanisms of microRNA deregulation in human cancer. Cell Cycle, 2008;7(17):2643-6.
12. Dvorak HF: Angiogenesis: update 2005. J Thromb Haemost, 2005;3(8):1835-42.
13. Elaimy AL, Mackay AR, Lamoreaux WT, et al.: Clinical outcomes of gamma knife radiosurgery in the salvage treatment of patients with recurrent high-grade glioma. World Neurosurg, 2013;80(6):872-8.
14. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer, 2006;6(4):259-69.
15. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med, 2003;9(6):669-76.
16. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995;1(1) 27-31.
17. Furnari FB, Fenton T, Bachoo RM, et al.: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev, 2007;21(21):2683-710.
18. Gabriely G, Yi M, Narayan RS, et al.: Human glioma growth is controlled by microRNA-10b. Cancer Res, 2011;71(10):3563-72.
19. Gaur AB, Holbeck SL, Colburn NH, et al.: Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neur Oncol, 2011;13(6):580-90.
20. Ge L, Hoa N, Bota DA, et al.: Immunotherapy of brain cancers: the past, the present, and future directions. Clin Dev Immunol, 2010;296453(10):8.
21. Gerstner ER, Batchelor TT: Antiangiogenic therapy for glioblastoma. Cancer J, 2012;18(1):45-50.
22. Godlewski J, Nowicki MO, Bronisz A, et al.: Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res, 2008;68(22):9125-30.
23. Gschwind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer, 2004;4(5):361-70.
24. Hegi ME, Diserens AC, Gorila T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 2005;352(10):997-1003.
25. Hou LC, Veeravagu A, Hsu AR, et al.: Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus, 2006;20(4):23-33..
26. Kano H, Kondziolka D, Lobato-Polo J, et al.: T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery, 2010;66(3):486-91.
27. Kefas B, Godlewski J, Corneau L, et al.: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res, 2008;68(10):3566-72.
28. Koga T, Maruyama K, Tanaka M, et al.: Extended field stereotactic radiosurgery for recurrent glioblastoma. Cancer, 2012;118(17):4193-200.
29. Koga T, Saito N: Efficacy and limitations of stereotactic radiosurgery in the treatment of glioblastoma. Neurol Med Chir, 2012;52(8):548-52.
30. Krzakowski M, Warzocha K, i wsp.: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złos̈liwych - 2013 r. Gdańsk: via Medica, 2013;1:33-68.
31. Kwiatkowska A, Nandhu MS, Behera P, et al.: Strategies in gene therapy for glioblastoma. Cancers, 2013;5(4):1271-305.
32. LI L, Quang TS, Gracely EJ, et al.: A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg, 2010;113(2):92-8.
33. Louis DN: Molecular pathology of malignant gliomas. Ann Rev Pathol 2006;1:97-117.
34. Louis DN, Ohgaki H, Wiestler OD, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 2007;114(2):97-109.
35. Lu J, Getz G, Miska EA, et al.: MicroRNA expression profiles classify human cancers. Nature, 2005;435(7043):834-8.
36. Lu YJ, Wei KC, Ma CC, et al.: Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. Colloids Surf B Biointerfaces, 2012;89:1-9.
37. Lv S, Teugels E, Sadones J, et al.: Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol, 2012;41(3):1029-35.
38. Mitchell PS, Parkin RK, Kroh EM, et al.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-8.
39. Mizoguchi M, Guan Y, Yoshimoto K, et al.: Clinical implications of microRNAs in human glioblastoma. Front Oncol, 2013;3(19):112-129.
40. Nduom EK, Hadjipanayis CG, Van Meir EG: Glioblastoma cancer stern; like cells: implications for pathogenesis and treatment. Cancer J, 2012. 18(1):100-6.
41. Odjele A, Charest D, Morin P, Jr.: miRNAs as important drivers of glioblastomas: a no-brainer? Cancer Biomark, 2012;11(6):245-52.
42. Park KJ, Kano H, Iyer A, et al.: Salvage gamma knife stereotactic radio; surgery followed by bevacizumab for recurrent glioblastoma multiformea case-control study. J Neurooncol, 2012;107(2):323-33.
43. Polverini PJ: Cellular adhesion molecules. Newly identified mediators of angiogenesis. Am J Pathol, 1996;148(4):1023-9.
44. Pouratian N, Crowley RW, Sherman JH, et al.: Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma. J Neurooncol, 2009;94(3):409-18.
45. Purow B: The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma? J Neurooncol, 2011;103(3):429-36.
46. Raizer J, Abrey LE, Lassman AB, et al.: A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neur Oncol, 2010;12(1):95-103.
47. Ren Y, Kang CS, Yuan XB, et al.: Co-delivery of as-miR-21 and 5-FU by poly (amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed, 2010;21(3):303-14.
48. Romanelli P, Conti A, Pontorieri A, et al.: Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme. Neurosurg Focus, 2009;27(6):211-222.
49. Salmaggi A, Boiardi A, Gelati M, et al.: Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia, 2006;54(8):850-60.
50. Scadden D. T.: The stem-cell niche as an entity of action. Nature, 2006;441(7097):1075-9.
51. Schuster M, Nechansky A, Kircheis R: Cancer immunotherapy. Biotechnol J, 2006;1(2):138-47.
52. Seshacharyulu P, Ponnusamy MP, Haridas D, et al.: Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets, 2012;16(1):15-31.
53. Sheehan J: Stereotactic radiosurgery for high-grade gliomas: available evidence and the need for further investigation. World Neurosurg, 2013;80(6):814-6.
54. Shirai K, Siedow MR, Chakravarti A: Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J Oncol, 2012;193436(10):14.
55. Stupp R, Hegi ME, Mason WP, et al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 2009;10(5):459-66.
56. Stupp R, Mason WP, ban der Bemt MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005;352(10):987-96.
57. Tanase CP, Enciu AM, Mihai S, et al.: Anti-cancer Therapies in High Grade Gliomas. Curr Proteomics, 2013;10(3):246-260.
58. Ujifuku K, Mitsutake N, Takakura S, et al.: miR-195, miR-455-3p and miR-10a (∗) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett, 2010;296(2):241-8.
59. Van Mieghem E, Wozniak A, Geussens Y, et al.: Defining pseudoprogression in glioblastoma multiforme. Eur J Neurol, 2013;20(10):1335-41.
60. Wang Z, Li Y, Kong D, et al.: Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett, 2010;292(2):141-8.
61. Weiner L. M., Surana R., Wang S.: Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol, 2010;10(5):317-27.
62. Wheeler CJ., Black KL, Liu G, et al.: Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res, 2008;68(14):5955-64.
63. Yoshida D, Takahashi H, Teramoto A: Inhibition of glioma angiogenesis and invasion by SI-27, an anti-matrix metalloproteinase agent in a rat brain tumor model. Neurosurgery, 2004;54(5):1213-20.
64. Zhu TS, Costello MA, Talsma CE, et al.: Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res, 2011;71(18):6061-72.